Background-Previous in vivo studies have shown that ␤-adrenoceptor agonists cause a redistribution of coronary flow away from the subendocardium; however, the underlying mechanism remains uncertain. We tested the hypothesis that a heterogeneous distribution of ␤-adrenoceptors and their vasomotor responses exists in the coronary microcirculation across the left ventricular wall. Methods and Results-Porcine subepicardial and subendocardial arterioles (Ͻ100 m) were isolated from the left ventricle and pressurized for in vitro study of vasodilation to the nonselective ␤-adrenoceptor agonist isoproterenol and the selective ␤ 2 -adrenoceptor agonist procaterol. Both vessel types developed a similar level of basal tone and dilated to isoproterenol and procaterol. However, subepicardial arterioles exhibited a much higher sensitivity and greater dilation capacity to both agonists. The isoproterenol-induced vasodilations were inhibited by glibenclamide, an ATP-sensitive potassium (K ATP ) channel blocker. In contrast to isoproterenol, dilations of subepicardial and subendocardial arterioles to pinacidil, a K ATP channel opener, were similar. In both vessel types, isoproterenol-induced dilation was inhibited by the ␤ 2 -adrenoceptor blocker ICI-118,551 but was insensitive to the ␤ 1 -adrenoceptor blocker atenolol. Reverse transcription-polymerase chain reaction and immunohistochemical data revealed that ␤ 2 -adrenoceptor mRNA and protein expression, respectively, were markedly greater in subepicardial arterioles. Conclusions-This study demonstrates that selective activation of ␤ 2 -adrenoceptors elicits dilation of both subepicardial and subendocardial arterioles through opening of K ATP channels. The higher ␤ 2 -adrenoceptor expression in subepicardial arterioles may contribute to the greater dilation of these vessels to ␤ 2 -adrenoceptor activation. (Circulation. 2004;110: 2708-2712.)
I t has been shown that direct activation of vascular ␤-adrenoceptors elicits dilation of both large and small coronary arteries in vitro, suggesting a possible role for these receptors in the regulation of coronary blood flow. 1, 2 The physiological relevance of this finding is supported by recent evidence showing that the activation of vascular ␤-adrenoceptors plays an important role in mediating feedforward sympathetic coronary vasodilation in response to exercise. 3, 4 Although the contribution of specific ␤-adrenoceptors was not determined in this study, it has been shown that the ␤ 1 -adrenoceptors are the predominant subtype in large coronary arteries 5 and that they mediate dilation of these vessels in vitro. 1 On the other hand, the ␤ 2 -adrenoceptor distribution 6 and dilation 2 appear to be predominant in small coronary arterioles. It appears that the coronary circulation exhibits a longitudinal heterogeneity in ␤-adrenoceptor distribution. Interestingly, previous in vivo studies have shown that ␤ 2 -adrenoceptor agonists cause redistribution of coronary blood flow away from the subendocardial region in normal 7, 8 and ischemic myocardium. 7 Although the underlying mechanism for this redistribution phenomenon remains uncertain, it was speculated that a heterogeneous transmural distribution of ␤-adrenoceptors and their vasomotor response may exist in the coronary microcirculation. However, this hypothesis has not been directly tested, and the distribution of specific ␤-adrenoceptor subtypes and their vasomotor function across the left ventricular wall have yet to be determined. Because coronary arterioles are the primary regulators of blood flow in the heart, 9 it would be important to understand the functional and molecular distribution of ␤-adrenoceptor subtypes in the subepicardial and subendocardial arterioles. Therefore, the present study was designed to determine the direct involvement of vascular ␤ 1 -and ␤ 2 -adrenoceptors in the dilation of subepicardial and subendocardial arterioles to the ␤-adrenoceptor agonist isoproterenol and the molecular distribution of ␤-adrenoceptors in these coronary microvessels.
Because ATP-sensitive potassium (K ATP ) channels have been suggested to be involved in the coronary vasodilation in response to ␤-adrenoceptor activation, 10 we also investigated the role of K ATP channels in the transmural vasodilatory response.
Methods

Functional Assessment of Isolated Coronary Arterioles
The procedures followed were in accordance with approved guidelines set by the Laboratory Animal Care Committee at Texas A&M University. See the online-only Data Supplement for detailed description of methods. Pigs (Milberger Farms, Kurten, Tex; nϭ18) were anesthetized with pentobarbital (20 mg/kg), and the heart was quickly excised. Individual left ventricular subepicardial and subendocardial arterioles were carefully dissected out for in vitro study, as described previously. 11 Vessels were cannulated and pressurized to 60 cm H 2 O intraluminal pressure. After development of stable basal tone, the vascular responses to cumulative extraluminal concentrations of the nonselective ␤-adrenoceptor agonist isoproterenol (0.1 pmol/L to 0.1 mol/L) and of sodium nitroprusside (1 nmol/L to 100 mol/L) were established. In some vessels, the response to the selective ␤ 2 -adrenoceptor agonist procaterol (0.1 nmol/L to 100 mol/L) was examined. To determine the contribution of specific ␤-adrenoceptor subtypes, the vascular response to isoproterenol was evaluated before and after treatment with the selective ␤ 1adrenoceptor antagonist atenolol (1 mol/L) 2, 12 or the selective ␤ 2 -adrenoceptor antagonist ICI-118,551 (1 mol/L). 2, 13 The role of K ATP channels in mediating vascular responses was assessed by the K ATP channel blocker glibenclamide (5 mol/L). 14
RNA Isolation and Reverse Transcription-Polymerase Chain Reaction Analysis
Total RNA was isolated from subepicardial and subendocardial arterioles (50-to 100-m inner diameter, 3 to 4 vessels per sample) and from myocardial tissue (positive control), as described previously. 15 Using primers specific for ␤ 1 -adrenoceptor, ␤ 2 -adrenoceptor, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes, reverse transcription-polymerase chain reaction was conducted as described previously. 15 
Immunohistochemical Analysis
Subepicardial and subendocardial arterioles (50-to 100-m inner diameter) were prepared for immunohistochemical analysis, as described previously. 15 Sections (12 m thick) were immunolabeled with a rabbit anti-␤ 2 antibody (1:40 dilution, Santa Cruz Biotechnology) and observed by means of confocal microscopy, as described previously. 15 
Data Analysis
Diameter changes in response to vasodilator agonists were normalized to the maximum diameter changes in response to 100 mol/L sodium nitroprusside and expressed as a percentage of maximal dilation. 14 
Results
Vasomotor Function and ␤-Adrenoceptor Activation
The isolated subepicardial and subendocardial arterioles had similar levels of basal tone (subepicardial: 70Ϯ5 m, 62Ϯ2% of maximal diameter versus subendocardial: 68Ϯ7 m, 66Ϯ2% of maximal diameter; PϾ0.05). Isoproterenol evoked a robust concentration-dependent dilation in the subepicardial vessels and only a modest dilation with the highest concentration (0.1 mol/L) in the subendocardial vessels ( Figure  1A) . The vasodilation threshold of subepicardial arterioles was 3 orders of magnitude more sensitive than that of subendocardial arterioles, and the maximal response at 0.1 mol/L isoproterenol was 4-fold greater in subepicardial microvessels. A significantly greater ␤ 2 -adrenoceptormediated dilation to procaterol, a selective ␤ 2 -adrenoceptor Figure 1 . A and B, Vascular reactivity of isolated porcine subepicardial (EPI) and subendocardial (ENDO) arterioles in response to isoproterenol (nϭ11 for EPI and ENDO) and procaterol (nϭ4 for EPI and ENDO). C and D, Dilation of EPI and ENDO arterioles to isoproterenol was examined in the absence and the presence of atenolol (nϭ7 for EPI and ENDO), ICI-118,551 (ICI; nϭ7 for EPI and ENDO), or glibenclamide (GB; nϭ4 for EPI and ENDO). nϭnumber of vessels. *PϽ0.05 vs EPI, control groups, or atenolol groups; †PϽ0.05 vs EPI-GB.
agonist, in subepicardial arterioles than in subendocardial arterioles was also observed ( Figure 1B ). Inhibition of ␤ 2adrenoceptors by ICI-118,551 almost completely blocked the isoproterenol-induced dilation of subepicardial arterioles ( Figure 1C ) and abolished the dilation of subendocardial arterioles ( Figure 1C ). In contrast, the ␤ 1 -adrenoceptor antagonist atenolol did not affect vasodilation to isoproterenol ( Figure 1C and 1D) . The subepicardial and subendocardial vessels dilated equally to sodium nitroprusside (1 nmol/L to 100 mol/L, nϭ3, see Data Supplement; PϾ0.05) and the responses were not altered by ICI-118,551, indicating that the ␤ 2 -adrenoceptor antagonist did not exert a nonspecific effect on vasomotor reactivity and that the vessels exhibited similar levels of vasodilatory capacity. The K ATP channel antagonist glibenclamide (5 mol/L) also inhibited vasodilation to isoproterenol ( Figure 1C and 1D ). Both vessel types dilated equally to pinacidil (1 mol/L) (subepicardial: 78Ϯ4% versus subendocardial: 74Ϯ6%; nϭ4), and the dilations were significantly (PϽ0.05) inhibited by glibenclamide (subepicardial: 13Ϯ6% versus subendocardial: 8Ϯ3%; nϭ4). It is noted that ICI-118,551, atenolol, and glibenclamide did not alter resting basal tone.
␤-Adrenoceptor Expression in Coronary Arterioles
The reverse transcription-polymerase chain reaction results showed that ␤ 2 -adrenoceptor but not ␤ 1 -adrenoceptor mRNA expression was detected in coronary arterioles, whereas both ␤-adrenoceptor subtypes were detected in myocardial tissue (Figure 2A ). Normalization of ␤ 2 -adrenoceptor transcripts with GAPDH transcripts exhibited a similar level of expression for all samples evaluated and showed that the expression of ␤ 2 was nearly 3-fold greater in subepicardial vessels than in subendocardial vessels (Figure 2A) . Similarly, immunohistochemical results revealed markedly greater signal intensity for ␤ 2 -adrenoceptor protein expression in subepicardial arterioles ( Figure 2B ).
Discussion
The activation of ␤-adrenoceptors in vivo has been shown to regulate myocardial perfusion by causing coronary vasodilation and increases in coronary blood flow. 8, 16 Because adrenergic activation in vivo can produce coronary vasodilation indirectly through myocardial ␤ 1 -and/or ␤ 2 -adrenoceptors (ie, increased heart rate and contractility leading to metabolic vasodilation) 17 or directly through vascular ␤-adrenoceptors, it can be difficult to discern the exact contribution of the direct vascular component. To gain insight into the involvement of specific vascular ␤-adrenoceptor subtypes in vasodilation, an isolated vessel preparation has been used. It has been shown that ␤ 1 -adrenoceptors are primarily responsible for the dilation of isolated large conduit coronary arteries. 1 In contrast, ␤ 2 -adrenoceptor activation mediates dilation of small resistance vessels isolated from the subepicardium. 2, 18 However, it has not been established whether specific ␤-adrenoceptor activation influences vasomotor tone in the subendocardium. In the present study, the response of ␤-adrenoceptor activation was investigated and compared in isolated and pressurized subepicardial and subendocardial arterioles. Isoproterenol (0.1 pmol/L to 0.1 mol/L), at the concentrations comparable to those used in vivo (10 nmol/L to 1 mol/L), 8, 16 elicited concentration-dependent dilation of isolated coronary arterioles, but the response was considerably greater in the subepicardial vessels. Isoproterenolinduced dilation in both vessel types was inhibited by ICI-118,551 but not by atenolol, indicating the primary functional role of ␤ 2 -adrenoceptors in these microvessels. It seems reasonable to postulate that a heterogeneous distribution of the ␤ 2 -adrenoceptor subtype could contribute to the differential response in the present study.
Further support for a heterogeneous ␤ 2 -adrenoceptor activation was provided by procaterol, a selective ␤ 2adrenoceptor agonist. Similar to isoproterenol, we observed a greater dilation of subepicardial arterioles to procaterol, and the dilation of subendocardial arterioles only occurred at higher concentrations (Ն10 mol/L). This is consistent with the in vivo findings that a relatively higher concentration of another ␤ 2 -adrenoceptor agonist, salbutamol (Ͼ1 mol/L), was required to increase subendocardial blood flow in the nonworking dog hearts after ␤ 1 -adrenoceptor blockade. 8 The disparity in the vasodilatory capacity to ␤ 2 -adrenoceptor agonists between subepicardial and subendocardial arterioles was apparently not a general phenomenon because the dilations of these vessels to pinacidil and sodium nitroprusside in the present study and to pinacidil and adenosine in our previous study 11 were very comparable.
The pharmacological results above support the hypothesis of a heterogeneous transmural distribution of ␤ 2adrenoceptors. Although differences in ␤ 2 -adrenoceptor density have been determined between large and small subepicardial coronary arteries by quantitative autoradiography, 6 it remains unclear whether receptor distribution, in particular at the molecular level, varies across the left ventricular wall. In agreement with the functional results, our molecular data provide the first evidence that ␤ 2 -adrenoceptor mRNA was predominantly expressed in both vessel types. However, the ␤ 2 -adrenoceptor mRNA and protein expression were significantly greater in the subepicardial vessels than in the subendocardial vessels. It appears that the differences in the sensitivity and magnitude of dilation to ␤-adrenoceptor agonists between subepicardial and subendocardial arterioles may result from the unequal distribution of ␤ 2 -adrenoceptors.
Although our findings do not support a role for ␤ 1adrenoceptors in coronary arteriolar dilation with isoproterenol, an earlier in vivo study has shown that blockade of ␤ 1 -adrenoceptors attenuates the isoproterenol-induced coronary blood flow. 16 A possible explanation for these apparently disparate results is that isoproterenol may stimulate ␤ 1 -adrenoceptors at upstream larger arterioles (Ͼ200 m in diameter), which have been shown to contribute some degree (Ϸ25%) 9 of coronary vascular resistance. Moreover, the ␤ 1 -adrenoceptors have been shown to be the predominant subtype in large coronary arteries, 5 and they mediate dilation of these vessels in vitro. 1 Therefore, it appears that large coronary arterioles/arteries exhibit ␤ 1 -adrenoceptors and possibly ␤ 2 -adrenoceptors, whereas small coronary arterioles, as shown in our present functional and molecular studies, exhibit predominately ␤ 2 -adrenoceptors.
Administration of the K ATP channel blocker glibenclamide in the coronary circulation has been shown to attenuate ␤ 2 -adrenoceptor-induced increases in myocardial blood flow, 10 suggesting that K ATP channel activation contributes to the dilation of coronary resistance vessels in response to ␤-adrenoceptor stimulation. This earlier study was not able to unequivocally determine whether arteriolar K ATP channels are directly involved in ␤-adrenoceptor-induced dilation because K ATP channel activations secondary to metabolic and hemodynamic disturbances during adrenoceptor activation are inevitable in the in vivo setting. In the present study, glibenclamide inhibited the dilation of subepicardial and subendocardial arterioles to the K ATP channel opener pinacidil and to isoproterenol, indicating a critical role for K ATP channels in the ␤ 2 -adrenoceptor-induced dilation of these vessels. However, it does not appear that K ATP channel signaling contributes to the transmural difference in vasodilation to ␤-adrenoceptor agonists because pinacidil-induced dilation was similar between subepicardial and subendocardial arterioles. These results further support the idea that the differential expression of ␤ 2 -adrenoceptors rather than the downstream signaling is responsible for the observed transmural difference in coronary arteriolar dilation to ␤-adrenoceptor activation.
The physiological or pathophysiological implications of the present results could provide further insight into the mechanisms contributing to regional differences in myocardial blood flow. In the normal heart, blood flow to the subendocardium is either equal to or slightly greater than that to the subepicardium. During exercise, sympathetic activation of vascular ␤-adrenoceptors can contribute to coronary vasodilation 3, 4 and the subendocardial flow is slightly redistributed toward the subepicardium. 19 For healthy individuals, this usually does not pose a grave situation, but for those with cardiovascular complications such as coronary stenosis, the redistribution of flow to the subepicardium is accentuated during exercise. 20 It is worth noting that myocardial ischemia is generally associated with elevated levels of norepinephrine. 21 Under this condition, the transmural difference in ␤ 2 -adrenoceptor activation, with preferential dilation in the subepicardium, could contribute, in part, to the apparent high vulnerability of subendocardium to ischemia. Indeed, in vivo studies indicate that activation of coronary ␤ 2 -adrenoceptors, independent of myocardial ␤ 1 -adrenoceptor activation, increases microvascular perfusion 22 and redistributes flow toward the subepicardial region in normal 7, 8 and ischemic myocardium. 7 Our findings may help to explain the observed differences in transmural blood flow during sympathetic activation and the greater susceptibility of subendocardium to ischemia that is exacerbated during exercise. 20 A better understanding of the functional and molecular mechanisms regulating subepicardial and subendocardial tone may yield new therapies for optimizing blood flow to different regions of the heart with ischemic disease.
